Also known as: Mitochondrial Open reading frame of the 12S rRNA-c
MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of the mitochondrial genome — one of the first peptides discovered to be encoded by mitochondrial rather than nuclear DNA. It acts as an exercise-mimetic, activating AMPK to improve insulin sensitivity, metabolic flexibility, and physical endurance.
MOTS-c was discovered in 2015 by Chang Hee Lee and colleagues at the University of Southern California. Its discovery overturned the established dogma that the mitochondrial genome only encodes for 13 proteins of the respiratory chain — revealing that mitochondria also produce regulatory peptides with systemic metabolic effects.
MOTS-c functions as a retrograde signal from mitochondria to the nucleus and other cells, coordinating metabolic responses to bioenergetic stress. Its plasma levels decline with aging in humans, and are lower in type 2 diabetic patients, suggesting it plays a physiological role in metabolic homeostasis. Exercise increases circulating MOTS-c, and exogenous MOTS-c supplementation produces exercise-like metabolic benefits even in sedentary animals.
MOTS-c activates AMP-activated protein kinase (AMPK) — the master cellular energy sensor — by modulating the folate cycle in a manner that increases AMP:ATP ratio. AMPK activation drives glucose uptake (via GLUT4 translocation), mitochondrial biogenesis (via PGC-1α), and fatty acid oxidation.
MOTS-c inhibits the folate cycle enzyme MTHFD1L, causing accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — a natural AMPK activator. This is distinct from other AMPK activators and explains MOTS-c's unique metabolic signature.
MOTS-c is banned by WADA (2024) as a peptide hormone with potential performance-enhancing effects. Human clinical data is very limited — most evidence from mouse studies. Endogenous MOTS-c levels rise naturally with exercise, particularly endurance training. Marathon runners show significantly higher circulating levels than sedentary controls.
Cycle protocols are based on preclinical mouse studies showing longevity and metabolic benefits with intermittent dosing (3×/week). Late-life (23.5 month) mice treated intermittently showed increased physical capacity and healthspan. No established human cycle protocol exists.
WADA-banned substance. Prohibited for use in competitive sports as of 2024. Research context only — not approved for human therapeutic use.
Ask anything about MOTS-c — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…